Compare Abbott Laboratories (ABT) vs DraftKings Inc (DKNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs DraftKings Inc — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while DraftKings Inc trades at $27.34 (market cap $13.35B). The key difference: Abbott Laboratories is far larger — about 12.5× DraftKings Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals.
| ABT | DKNG | |
|---|---|---|
Market Cap | $166.94B | $13.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $48.23 |
52-Week Low | $82.57 | $20.72 |
Enterprise Value | $193.69B | $14.27B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
DraftKings (DKNG) trades at $26.91, up 3.94% today, with a bearish technical signal but strong analyst consensus. Revenue grew to $6.05B in 2025, achieving positive net income of $3.71M, a significant turnaround from prior losses. The launch of the DKeX prediction market exchange (Business Wire, 2026-06-26) and record sportsbook engagement during the 2026 World Cup (Benzinga, 2026-06-26) highlight growth initiatives, though profitability remains thin with a P/E of 291.22.
The outlook is mixed: robust revenue growth and a $34.25 analyst price target suggest upside, but high valuation, competitive pressures, and regulatory risks pose challenges. Positive cash flow from operations of $662.86M in 2025 supports stability, yet volatility near key resistance at $27 requires monitoring for sustained bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →
